Pfizer drug candidate shows strong results in tough breast cancer study
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
Subscribe To Our Newsletter & Stay Updated